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Abstract: Extracellular vesicles (EVs) are membrane-bound lipid particles that are secreted by all
cell types and function as cell-to-cell communicators through their cargos of protein, nucleic acid,
lipids, and metabolites, which are derived from their parent cells. There is limited information
on the isolation and the emerging therapeutic role of periodontal and dental pulp cell-derived
small EVs (sEVs, <200 nm, or exosome). In this review, we discuss the biogenesis of three EV
subtypes (sEVs, microvesicles and apoptotic bodies) and the emerging role of sEVs from periodontal
ligament (stem) cells, gingival fibroblasts (or gingival mesenchymal stem cells) and dental pulp
cells, and their therapeutic potential in vitro and in vivo. A review of the relevant methodology
found that precipitation-based kits and ultracentrifugation are the two most common methods to
isolate periodontal (dental pulp) cell sEVs. Periodontal (and pulp) cell sEVs range in size, from
40 nm to 2 µm, due to a lack of standardized isolation protocols. Nevertheless, our review found
that these EVs possess anti-inflammatory, osteo/odontogenic, angiogenic and immunomodulatory
functions in vitro and in vivo, via reported EV cargos of EV–miRNAs, EV–circRNAs, EV–mRNAs
and EV–lncRNAs. This review highlights the considerable therapeutic potential of periodontal and
dental pulp cell-derived sEVs in various regenerative applications.
Keywords: extracellular vesicles; exosomes; nanomedicine; regeneration; cell-free therapy
1. Introduction
Extracellular vesicles (EVs) are membrane-bound bilayered lipid particles that are
secreted from both prokaryotic and eukaryotic cells, carrying a cargo of biological molecules
(i.e., protein, nucleic acid, lipids and metabolites) from their parent cells [1]. Initially, EVs
were considered ‘cellular dust’, generated by cellular metabolism, until their biological
role in the mineralization of bone was recognized [2,3]. A principal role of EVs is as an
intercellular communicator of biological information into a recipient cell. This interaction
can trigger signaling cascades and modulate cell behavior [4]. The biological function of
EVs is defined by the parent cells from which they originate. EVs are involved in almost all
cellular interactions, especially tumor metastasis, tissue homeostasis, and inflammatory
regulation [4,5]. Due to their constituent biological molecules, EVs hold great promise as a
therapeutic delivery system in regenerative medicine.
The definition, terminology and subtypes of EVs are still being debated. The Inter-
national Society of Extracellular Vesicles (ISEV) recommends a division of EV subtypes
based on their size: medium/large EV (>150 nm) and small EV (<150 nm) [6]. However,
considering the discrepancies in the published literature, for simplification purposes, this
review will define EV subtypes based on both their size and biogenesis (Figure 1a): small
extracellular vesicles (also known as exosomes) (sEVs, <200 nm), microvesicles (MVs,
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50–1000 nm) and apoptotic bodies (ApoBDs, 50–2000 nm). Furthermore, it is notewor-
thy that all EVs have various membrane proteins (e.g., tetraspanin, MHC, and HSP) and
components (e.g., dsDNA, RNA, microRNA, circular RNA [7], and proteins) (Figure 1b).
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1.1. Small EV (Exosomes)
Small EVs (sEV), or exosomes, originate from endosomes, and are biological nanopar-
ticles that are smaller than 200 nm [5]. Further, sEVs are produced through an endocytic
pathway, and their particle size is partially overlaid with that of microvesicles and apop-
totic bodies. The biogenesis process for sEV is unique, whereby the endosomal network
is the source of sEV that produce, classify, distribute and define the proper destination
of the secreted sEV [2,8]. Endosome production can be categorized into the following
three subtypes, according to each stage of development: early endosomes, late endosomes,
and recycling endosomes. Early endosomes are formed by inward budding of the cell
membrane, before a second inward budding of the endosomal membrane that results in
the formation of late endosomes—intraluminal vesicles (ILVs). Late endosomes containing
IVLs are named multi-vesicular bodies (MVBs), and the MVBs either fuse with lysosomes
to degrade or follow the endocytic pathway for sEV generation. Once fusion with the
plasma membrane is completed, the small membrane-enclosed vesicles are released into
the extracellular matrix.
The biogenesis of sEV is affected by the following two main pathways that can induce
multi-vesicular bodies (MVBs) generation: the endosomal sorting complex, required for
the transport (ESCRT)-dependent pathway and ESCRT-independent pathway [9]. For
the ESCRT-dependent p thway, ESCRT I and ESCRT II m diate the invagi ation of the
late endosomal membrane, and ESCRT III will be r cruited to the i vaginated membrane
sites. The cargo proteins are then deubiquiti ated, and this stimulates the departur of
the vesicl and the formation of MVBs. In the ESCRT-inde endent pathway, the neutral
sphigomyli ase2 (nSMas 2) takes sphingolipids a sub tr tes and converts sphingolipids
to ceramide at the endosomal embrane. F llowing this, the microdomain is prepared for
merging into a lar ccelerates the endosomal bud ing and biogenesi of
MVBs [10]. Moreover, sEVs that re produced by these different pa hways po ses different
biomarkers, except CD63, which is the most com on biomarker f r sEVs [ 1,12].
With respect to the ESCRT-dependent pathway, if endocytosis is mediated by Ras-related
protein 27A/B (RAB27A/B), TSG101 is a biomarker of sEV. If the endocytosis is mediated
by phospholipase D2 (PLD2) and RAB7, through the ESCRT-independent pathway, the
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biomarkers of sEV are alix, syntenin, and syndecan. As for the RAB11/35-mediated
ESCRT-independent pathway, CD81, Wnt and proteolipid protein (PLP) are the preferred
biomarkers.
The function of sEV in intercellular communication is determined by the interconnec-
tion between sEV surface proteins and receptors on the recipient cells that subsequently
activates a variety of signaling pathways [5]. Further, sEVs arising from different cell
types have different cargos that dictate and direct different biological effects. The sEVs are
highly abundant in biofluids [13–15], and they have been demonstrated to be associated
with immune response, viral pathogenicity, osteogenesis, odontogenesis, neuroprotection,
angiogenesis, and anti-tumor functions [16]. For example, oral cancer cell-derived sEVs
create a mechanism that can promote tumor progression by modifying vesicular contents
and establishing a distant premetastatic niche with molecules that favor cancer cell pro-
liferation, migration, invasion, metastasis, angiogenesis, and even drug resistance [17].
Evidence that sEVs play an important role in cell differentiation suggests that sEVs may
have a potential role in tissue regeneration.
1.2. Microvesicles
Microvesicles (MVs) are membrane vesicles of different sizes, surrounded by a lipid
layer of membrane, and they range in size from 50 nm to 1 µm. Microvesicles are generated
by the outward budding of the plasma membrane, and are abundant in tissues/cells and
biofluids [18]. The contents of MVs are similar to that of sEV. The MV components of note
include CD40, selectins, integrins, cytoskeletal proteins, and cholesterol [19].
The biogenesis of MV involves the contraction of cytoskeletal proteins and phospho-
lipid redistribution, contributing to a dynamic interplay in the plasma membrane and the
resultant formation of microvesicles. Within the plasma membrane, the aminophospho-
lipid translocase regulates phospholipid distribution, transferring phospholipids from one
leaflet to another. Once phosphatidylserine (PS) is translocated to the leaflet of the outer
membrane, the outward blebbing of the membrane and microvesicle formation is initiated.
The interaction between actin and myosin causes the cytoskeletal structure contraction,
which mediates membrane budding [20].
MVs have been reported to maintain tissue homeostasis during tissue regeneration,
angiogenesis, anti-tumor effects, and in pathologies such as tumorigenesis, chronic inflam-
mation, and atherosclerosis [19]. MVs that are produced by blood cells (e.g., neutrophils,
macrophages, and platelets) are involved in the pro-coagulatory response [21]. MVs can
be both pro-inflammatory and anti-inflammatory; this is determined by the induction or
stimulation that is received by their parent cells. MVs that are produced by tumor cells
enhance invasiveness and accelerate cancer progression, as well as strengthen the drug
resistance of tumor cells [22]. This indicates that MVs are potential therapeutic agents
for tissue regeneration; however, the function of MVs in periodontal tissue healing and
regeneration requires further investigation.
1.3. Apoptotic Bodies
Apoptotic bodies (ApoBDs) are produced by cells undergoing apoptosis, and vary
in size from 50 nm to 2 µm [23,24]. ApoBDs result from the formation of subcellular
fragments when an apoptotic cell disassembles. They are comprised of molecular com-
ponents from living cells and provide a rich molecular pool for recipient cells. However,
ApoBDs are engulfed by macrophages and digested by phagolysosomes shortly after they
are released [25]. ApoBDs and apoptosis are not related to an inflammatory reaction, the
constituents in dying cells and ApoBDs are not released automatically to the environ-
ment, and anti-inflammatory cytokines are not generated during engulfing. ApoBDs have
phosphatidylserine (PS) on their surfaces, to attract engulfing cells, and are considered to
be specific biomarkers for ApoBDs [26]. Autoimmune diseases may be associated with
defects in the clearance of ApoBDs. ApoBDs may stimulate the formation of thrombus and
improve anti-cancer immunity.
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Increasing evidence suggests that ApoBDs have important immune regulatory roles,
in autoimmunity, cancer, and infection [24], as well as promoting osteogenesis [27]. For
example, ApoBDs that are derived from mature osteoclasts can induce osteoblast dif-
ferentiation by activating the protein kinase B/phosphoinositide 3-kinases (PI3K/AKT)
pathway [27]. However, knowledge of their function and role is still limited and more
studies are required in this field.
2. The Source and Characteristics of Periodontal (Dental Pulp) Cells
Dental tissue-derived (or stem) cells have remarkable characteristics for therapeutic
application, being easily accessible and a rich source of stem cells with a well-known
regenerative capacity. A great variety of multipotent adult or postnatal stem cells can be
retrieved from dental tissues, especially from periodontal tissue and dental pulp from
extracted permanent teeth (dental pulp stem cells—DPSCs) and exfoliated deciduous teeth
(SHED). A healthy periodontium consists of soft (periodontal ligament-PDL and gingiva)
and hard (alveolar bone and cementum) tissue, and cells residing within the healthy
periodontal tissues include periodontal ligament (stem) cells (PDLSCs), PDL and gingival
fibroblasts (PDLF, GFs), or gingival stem cells (GMSCs), osteoblasts (OBs), osteoclasts
(OCs), and various immune cells (Figure 2) [28,29]. Moreover, stem cells can be obtained
from dental apical papilla tissues (SCAP) and dental follicles (DFSCs, or DFCs) of the
developing tooth [28,29]. Importantly, EV that is derived from these cells can be detected
within periodontal tissues and biofluid (i.e., gingival crevicular fluid) (Figure 2).
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Figure 2. s o ing the main cell population and cell products (EVs) within a healthy
peri dontium. Various cells reside in the periodontium, s ch ri t l liga e t (stem) cells
(PDLSCs), fibroblasts (GFs) and stem cells (GMSCs) from the gingiva, osteoblasts (OBs), osteoclasts
(OCs), and various immune cells. AB: alveolar bone; C: cementum; D: dentin; DP: dental pulp;
PDL: periodontal ligament; SHED: dental pulp cells from human exfoliated deciduous teeth (SHED);
SCAP: cells from periodontal apical papilla tissues (SCAP).
Dental mesenchymal stem cells originate from the neural crest ectomesenchyme and
reside in stromal niches (perivasculature and peripheral nerve-associated glia cells). The
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current consensus holds that both perivascular cells [30] and glia cells [31] are responsible
for dental MSCs origin, as revealed in mouse experiments [31]. Much like bone-marrow-
derived MSCs that originate from mesoderm [32], dental stem cells express MSCs markers
and exhibit multipotent linage regeneration (i.e., osteogenic, chondrogenic, neurogenic)
and immunomodulatory capabilities. These properties make these cells suitable candi-
dates for therapeutic application (reviewed by Chalisserry et al. in [33]) in neurological
disorders, angiogenesis, dentin-pulp regeneration and periodontal regeneration. PDLSCs,
GFs, DPSCs, SHED, and DFSCs have been demonstrated to promote multiple-tissue re-
generation, both in vitro and in vivo [34–40]. However, cell therapy has several challenges,
including high cost, insufficient cell number, and associated regulatory barriers. On the
other hand, a cell-free approach, centered around cell products (i.e., EVs derived from
these cells), has been proposed, and there is an emerging focus on cell-derived EVs as
potential therapeutic agents to promote periodontal regeneration. The utilization of sEVs
for dental tissue regeneration is emerging as a viable cell-free treatment option, with ‘proof
of concept’ studies reported using bone marrow or adipose MSC-derived sEVs (reviewed
in [41–43]); yet, periodontal or dental pulp cell sources are likely to uniquely reflect the
functional complexity of the periodontium and oral cavity.
The following sections will summarize the current methods for cell-derived sEV
isolation and characterization, with particular emphasis on sEVs from periodontal and
dental pulp cells.
3. Cell-Derived sEV Isolation Methods
3.1. General Concepts
Although sEVs have been studied for decades, there is still no standardized protocol
for their isolation. Despite the presence of recommended guidelines for EV isolation and
characterization, such as the Minimal Information for Studies of Extracellular Vesicles 2014
(MISEV2014) and MISEV 2018, these guidelines are not always followed.
Prior to the isolation of sEV, sequential centrifugation is commonly used to remove
cell debris and large EVs, as follows:
i Step 1: the cell conditional media (CM) is harvested and centrifuged at 300–400× g to
remove cells, and the supernatant (SN) is collected;
ii Step 2: the SN collected in step 1 is centrifuged at 2000–3000× g to remove cells debris
and apoptotic bodies. The SN is collected from this step;
iii Step 3: SN from step 2 is centrifuged at 10,000–20,000× g to remove the aggregates of
biopolymers, microvesicles, and the other structures with a buoyant density higher
than sEVs. The SN is collected from this step;
iv Step 4: then, the following isolation methods are used to enrich the sEVs: ultracentrifu-
gation, sucrose gradient centrifugation, size exclusion chromatography, precipitation-
based isolation, immunoaffinity chromatography, and ultrafiltration.
Given the growing interest in EVs, technical standardization is critical, as many
different methodologies have been utilized for isolation and analysis. The influence of
these various techniques on the downstream composition and functionality of EV cargos
remains unclear; accordingly, the ISEV position papers [6,44] have raised the need to define
‘good practices’ and ultimately archive standardization. However, many researchers are
not following these four steps, due to a lack of standardized protocols. Here, our review
briefly introduces each isolation method, and discusses its merits and disadvantages (listed
in Table 1).
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Table 1. Representative advantages and disadvantages of various EV isolation methods.




1.5 h to 10 h
• Well-known ‘gold-standard’
method
• Easy to access
• Straightforward methodology
• Low recovery rate of sEV
• Time consuming (normally will
need 2 steps of UC)





250 min to 1 day
• Pure EV population
• No protein contamination







• Pure EV product







• Low-speed centrifuge (1500 g)
to retrieve the sEV sample
• Straightforward method
• Many samples can be
processed
• Low EV recovery
• Co-precipitation of protein and
other molecules




• Very pure EV subpopulation
(i.e., CD9+ EV)




• Small sample volume
• Simple procedure
• Higher yield than UC method
• High contamination of non-EV
protein
3.2. Ultracentrifuge
Ultracentrifugation is the gold-standard method for isolating sEV, as the equipment is
relatively easy to access and the methodology is technically straightforward. The method
involves an ultracentrifugation step at 100,000×–200,000× g to pellet sEV [45]. However,
ultracentrifugation has disadvantages, in that it leads to a low recovery rate of sEV, it is
time consuming (1.5–10 h), contains non-vesicular macromolecule contamination, and
results in EV aggregation.
3.3. Floatation-Related Methods (Sucrose Gradient Centrifugation)
Floatation-related methods distribute molecules based on the buoyant density, and the
protein aggregates and sEV can be sufficiently separated. Differential gradient centrifuga-
tion (usually takes 250 min—1 day) takes advantage of buoyant density to fractionate EVs
using sucrose or idoxanol gradients [45]. The sEVs can be separated by the discontinuous
gradient sucrose solution, with each layer containing the desired size of EV. Other chemical
reagents (i.e., iodixanol) can also be utilized instead of sucrose, for continuous EV harvest
with no layers. Non-vesicular protein contaminants are distributed at a reduced level
within this method, resulting in less protein contamination. However, sucrose gradient
centrifugation cannot separate large particles that have a similar sedimentation rate.
3.4. Size Exclusion Chromatography (SEC)
SEC can be used to isolate small sEV, based on the size of the molecules, where large
particles pass through the gel earlier than the small-sized molecules. The small-sized
particles are trapped in the tiny pores on the surface of the gel, while the larger molecules
can bypass the gel or receive less interference from the gel [46]. This technique has been well
established with commercialized SEC columns, including qEV (iZON Science), Exo-spin™
SEC columns (Cell Guidance Systems Ltd.) and Pure-EVs SEC columns (HandaBioMed,
Lonza). SEC has been proposed as an effective alternative method for pure sEV isolation,
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with a key advantage being its time efficiency (~30 min, including 10 mL of column washing
with PBS). However, the similarly sized sEV and microvesicles cannot be separated by SEC.
3.5. Precipitation-Based Isolation (Sodium Acetate, PEG, Protamine)
Precipitation-based isolation has the following two mechanisms: polymeric precipi-
tation and neutralizing charges [47]. In polymeric precipitation, a soluble polymer, usu-
ally polyethylene glycol (PEG), is mixed with EV samples and the mixture is incubated
overnight, and EVs are sedimented by low-speed centrifugation at 1500 g. PEG precipi-
tation enables a simple process for a large number of samples. Commercial kits, such as
ExoQuick (System Biosciences), total exosome isolation reagent (Invitrogen), EXO-Prep
(HansaBioMed), exosome purification kit (Norgen Biotek), and miRCURY exosome iso-
lation kit (Exiqon), are based on this principle. For the other precipitation method, all
EVs possess negative charges, so positively charged molecules (i.e., sodium acetate and
protamine) are chosen for the precipitation. This method is popular due to its straight-
forward protocol; however, these precipitation methods lead to low sEV purity due to
co-precipitation of the components from CM or biofluids, such as protein, DNA and RNA,
and hence further purification is required.
3.6. Immunoaffinity Chromatography
The monoclonal antibodies (mAbs) against specific sEV surface proteins (i.e., CD 9)
are fixed on the column, to capture a specific sEV population [48]. Once the CM passes
through the column, the EVs, which express certain exosomal markers on their membrane,
will be captured by the mAbs. This method leads to a very pure EV population, but low
yield and scalability. This is attributed to the fact that this step needs to be repeated several
times to ensure the mAbs can capture sufficient EVs (~240 min).
3.7. Ultrafiltration
Semi-permeable membranes (ranging from 3 kDa to 100 kDa) are adapted for sEV
fractionation within filtration-based isolation; the membrane function is determined by its
pore size. However, sEVs cannot be fractionated according to their biogenesis or biomark-
ers, but it is normally used to concentrate sEVs. It is still an efficient way to eliminate the
minimal sample volume (~130 min) with a simple procedure, and has been proven to yield
higher recovery of sEVs than ultracentrifugation [49]. However, ultrafiltration might lead
to low EV protein, but a rather higher concentration of non-EV proteins (i.e., albumin).
3.8. Current Isolation Challenge
As mentioned previously, the current challenges of sEV isolation include time-consuming
procedures, impurities, insufficient EV yield, and low scalability [50]. Although many
researchers have investigated combinations of these isolation methods, an urgent demand
has arisen to investigate high-yielding and time-effective isolation protocols. Currently,
there is no optimal sEV isolation method; however, a combination of ultracentrifugation,
SEC, and ultrafiltration has been used for the pure sEV population, which is a critical factor
for downstream therapeutic applications.
4. sEV Isolation and Characterization Methods for Periodontal (and Dental Pulp) Cells
To date, there are no standardized protocols for sEV isolation and characterization.
From the 33 studies that are reported in this review, we have summarized periodontal (den-
tal pulp) cell-derived sEV isolation and characterisation methods [51–83]. Various isolation
methods have been used for periodontal (dental pulp) cells sEVs, including ultracentrifu-
gation (UC), precipitation-based methods, and ultrafiltration (Figure 3a). Regarding EV
characterization, the latest MISEV 2018 guidelines [6] suggest that all EV researchers should
characterize sEV from at least three different aspects, such as EV particle numbers, EV
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morphology, and EV-enriched protein markers. However, most of the current studies did
not follow the MISEV guidelines, and this requires additional attention for all EV research.
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this review), WB is the most commonly used characterization method (n = 7 studies), fol-
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assay (n = 1), ELISA (n = 1), and confocal microscopy (n = 1). In GFs/GMMSCs–sEVs, WB 
(n = 4) was utilized to detect CD9, CD63, and TSG101, as well as TEM (n = 4), NTA (n = 3), 
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Figure 3. Various sEV isolation methods (a) and characterization methods (b) are used for periodontal (dental pulp) cells.
UC: ultracentrifugation; NTA: nanoparticle tracking analysis; TEM: transmission electron microscopy; WB: Western blot;
SEM: scanning electron microscopy; AFM: atomic force microscopy; BCA: bicinchoninic acid assay; DLS: dynamic light
scattering; ELISA: enzyme-linked immunosorbent assay; confocal: confocal microscopy.
Different sEV isolation methods have been utilized for various cells (Figure 3a), with
precipitation and ultracentrifugation methods being the two most commonly used tech-
niques. In PDL(S)C-derived sEV isolation (10 studies), the precipitation-based method
(i.e., a commercial ExoQuick kit) is the most commonly used (n = 6, 60%), followed by
ultracentrifugation (n = 4, 40%). Among six studies in GFs/GMSC-derived sEVs, the
precipitation-based method (n = 4, 66.7%) and ultrafiltration (n = 2, 33.3%) were used for
GFs/GMMSCs–sEV isolation. Regarding DPSC-derived sEV, most researchers selected
ultracentrifugation (n = 7, 77.8%), with one study using the precipitation-based method
(n = 2, 22.2%). For SHED–sEVs, all of the studies (n = 4, 100%) used the ultracentrifugation
method to isolate sEVs from SHED.
Concerning EV characterisation [6], NTA and DLS are common methods to quantify
EV particle number, size, and distribution; TEM, SEM, and AFM can be used for EV
morphology and size; BCA is for EV protein quantification; and WB is to determine EV-
enriched protein markers. We have summarized the various EV characterisation ethods
for periodontal cell-derived sEVs (Figure 3b). For PDL(S)Cs—sEV (10 studies included
in this review), WB is the most commonly used characterization method (n = 7 studies),
followed by TEM (n = 5), NTA (n = 3), AFM (n = 2), flow cytometry (n = 2), SEM (n = 1),
BCA assay (n = 1), ELISA (n = 1), and confocal microscopy (n = 1). In Fs/GMMSCs–sEVs,
WB (n = 4) was utilized to detect 9, CD63, and TSG101, as well as TEM (n = 4), NTA
(n = 3), DLS (n = 2), BCA assay (n = 2), AFM (n = 1), and FACS (n = 1). The characterisation
of DPSC–EVs are mostly performed using WB (n = 7), TEM (n = 8), NTA (n = 6), BCA
assay (n = 3), FACS (n = 2), and dot blot (n = 1). For the charac erization of SH D–sEVs (4
studies), TEM and WB (n = 4) are m st c mmonly applied; NTA (n = 3) and BCA (n = 2)
were also used for OBs–sEVs.
, lt i t t
l s is l ti .
NTA are the most common methods for periodontal (dental pulp) cell-derived sEVs char-
acterisation.
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5. The Function of sEVs Derived from Periodontal (Dental Pulp) Cells
Current studies mainly focus on small EV biogenesis and function in the periodontal
regeneration field; thus, this review summarizes 33 studies [51–83] on periodontal cell-, gin-
gival cell- and dental pulp (DPSCs and SHED) cell-derived sEV isolation, characterization,
and their therapeutic role in tissue regeneration. Most of this research has focused on the
function of sEVs in cell differentiation, and 11 studies investigated the cargos of sEVs (i.e.,
miRNA [52,53,61,63,64,72,75,81], circRNA [51,71], lncRNA [51], and EV-mRNA [67,72])
during this process.
5.1. Periodontal Ligament Fibroblasts or Stem Cells (hPDL(S)Cs)–sEV
A total of 10 studies investigated sEVs derived from human PDL (stem) cells or
fibroblasts [51–60], and are summarized in Table 2. Eight studies isolated sEV from
hPDLSCs [51–53,55,56,58–60], with one study each using sEVs from a human PDL fi-
broblast (hPDLFs) cell line [54] and hPDLCs [57]. Three of these studies investigated
hPDLCs sEV function in vivo, using animal models [56,59,60].
According to the latest MISEV 2018 guidelines [6], it is critical to consider several
factors influencing the collection of EV, including characteristics of primary cell source
(donor health status, age, gender), primary cell passage number, confluence at harvest,
culture volume, media change frequency, CM harvesting conditions, as well as all culture
media composition and preparation details. Thus, our review includes detailed donor
information for primary cells (if mentioned), the cell culture condition prior to CM collec-
tion, and detailed sEV isolation protocols. This will allow future EV researchers to select
appropriate protocols for CM harvesting and sEV isolation.
Donor age was disclosed in only two studies (18–30 [51] and 18–21 years old [55]),
while there is no clear information in the other studies [52–54,56–60]. The cells at passages
2–3 were used in five studies [51–53,56,59], passage 3–7 in one study [54], with no passage
information provided in the remaining studies [55,57,58,60]. Since fetal calf serum (FBS
or FCS) contains a large amount of EV, it is crucial to state how cells are cultured before
CM harvesting. Currently, either EV-depleted FBS or FBS starvation is used before CM
harvest for PDLCs–sEV isolation; from the 10 studies that were reviewed, 5 did not state
how the cells were cultured before CM collection [53,56,58–60], 4 studies used EV-depleted
FBS [52,54,55,57], and one study used FBS starvation [51]. While it is of considerable
importance to clearly articulate the cell source, passage number, and CM harvest condition,
this is something that is currently under-reported in many studies.
The following three aspects of hDPL(S)Cs–sEV analysis were evaluated in the 10
studies that have been included in this review: (1) EV size, (2) EV content (protein, RNA,
etc.), and (3) EV function in cell differentiation in vitro and in vivo. Regarding the size of
hPDL(S)Cs–sEV, three studies did not characterize the sEV size [52,53,60]. There is a large
deviation for the reported EV size: <200 nm in five studies [51,54,55,57,58], two populations
(90 ± 20 nm and 1200 ± 400 nm) in one study [59], and 100–710 nm in one study [56].
It is noted that two studies engineered the hPDLCs–EV using polyethyleneimine (PEI,
yielding PEI–EV) [56,59]. The following two factors may contribute to this deviation:
the EV isolation method (UC or precipitation methods), and the EV size characterization
methods (TEM, or DLS, or NTA). We will define EV size <200 nm as sEV, and unclear EV
size as EV.
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Table 2. The isolation, characterization, and function of PDL(S)C-derived EVs.
Reference Cell Source EV Isolation EV Characterization Key Findings
Xie et al., 2021 [51]
• hPDLSCs
• Donor: Healthy patients aged
18–30 years old, with no
system diseases, underwent
impacted third molar or
orthodontic extractions
• Passage 3
• FBS starvation for 48 h
• 3000 g for 20 min; 16,500 g for
20 min; 0.2 µm filter;




• Exosomes from hPDLSCs
before (EX0) and after
osteogenic induction for 5




• WB (CD63 and CD81)
• The size of sEV ranged from 20 to 100 nm.
• 69–557 sEV–circRNAs and 2907–11,581 exosomal
lncRNAs were found in EX0, EX5 and EX7 by
RNA sequencing.
• Within hPDLSCs—exosomes, compared with
EX0, 3 circRNAs and 2 lncRNAs were
upregulated and 39 circRNAs and 5 lncRNAs
downregulated in EX5 and EX7.
• Exosomal circRNAs may function as competing
endogenous RNAs through a
circRNA–miRNA–mRNA network via TGF-β
pathway, MAPK pathway, mTOR pathway and
FoxO signaling pathways during hPDLSCs
osteogenic differentiation in vitro.
Zhang et al., 2020 [52]
• hPDLSCs
• Donors: Periodontal ligaments




• hPDLSCs were cultured with a
vesicle-free medium.
• Centrifuge for 10 min at 500×
g, 30 min at 16,000× g;




• WB (TSG101 and
CD63)
• SEM
• EV size was not mentioned.
• When co-cultured with TNF-alpha, the
angiogenesis of HUVECs was promoted by
hPDLSCs exosomes.
• The angiogenesis of HUVECs was
downregulated when the secretion of exosomes
was blocked.
• Inflammation influenced pro- angiogenesis of
hPDLSCs via regulating the exosome-mediated
transfer of VEGFA targeted by miR-17-5p.
Chiricosta et al., 2020 [53]
• hPDLSCs
• Donor: Five healthy patients
from tooth removal for
orthodontic purposes
• Passage 2
• Conditioned medium of
hPDLSCs at (CM; 10 mL) after
48 h of incubation.
• 15 min at 3000× g; mixed with
ExoQuick TC reagent at 4 ◦C





• EVs size was not mentioned
• The EV derived from hPDLSCs contain several
non-coding RNAs, especially the following five
miRNAs: miR24-2, miR142, miR296, miR335, and
miR490. The target genes of these miRNAs are
involved in Ras protein signal transduction and
actin/microtubule cytoskeleton organization.
Nanomaterials 2021, 11, 1858 11 of 34
Table 2. Cont.
Reference Cell Source EV Isolation EV Characterization Key Findings
Zhao et al., 2019 [54]
• Human periodontal ligament
fibroblasts (hPDLFs) cell line
• MG-63 osteoblast cells line
• Passages 3–7
• P. gingivalis LPS-treated
hPDLFs for 4 h and cultured
with exosome-depleted
FBS/1% PS for another 24 h.
• 1000× g for 10 min and
10,000× g for 15 min, 0.22 µm
Millipore filter; concentrated
CM (3–5 mL) using a 100 kDa
ultracentrifuge filter at 5000×
g in for 30 min; ExoQuick-TC
reagent was added and
incubated with CM overnight,
centrifuge the mixture at





• WB (CD9, CD63,
TSG101)
• Exosomes size: 70–100 nm, peaked at 84 nm.
• Exosome-enriched protein and total exosomal
protein levels were higher in the LPS-treated
hPDLFs than those in non-LPS-treated hPDLFs.
• Upregulated IL-6, TNF-α and inhibited
expression ALP, collagen-I, RUNX2, and OPG
were found in MG-63 OBs after uptaking the
exosomes derived from LPS-treated hPDLFs.
Čebatariūn-ienė et al., 2019
[55]
• hPDLSCs grew in a bioreactor
on gelatin-coated microcarriers
• Donor: healthy periodontal
tissues of two Caucasian
females (18 and 21 years old)
using explant outgrowth
method
• Supernatants (SN) from
PDLSC in basal medium
supplemented with 10% of
EV-depleted FCS every 72 h
• All centrifugation steps were
performed at 4 ◦C
• 300 g for 10 min, 2000 g for 10
min; 20,000 g for 30 min; then
ultracentrifuged at 100,000× g
for 70 min.
• The pellets were washed in 40
mL PBS and ultracentrifuged
again at 100,000× g for 70 min
• TEM
• NTA
• WB (CD63, MFG-E8)
• The size of sEV derived from microcarrier cell
cultures of PDLSCs: 112–182 nm.
• hPDLSCs–sEV suppressed basal and
LPS-induced activity of NF-kB in PDLSCs.
• Combined treatment with EV and anti-TLR4
antibody attenuated the inhibitory effect on the
NF-kB activity
• Uptake of hPDLSCs–sEV in hPDLSC-activated
phosphorylation of Akt and GSK3β (Ser 9)
indicating that PI3K/Akt signaling pathway may
act as a suppressor of NF-kB activity
• EVs did not significantly affect osteogenic
mineralization of hPDLSCs cultures, but EV
significantly increased expression of ALP, OPN,
BSP, and CP23 gene expression, but
downregulated BMP2 expression on the 10 days
of osteogenic differentiation.
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Table 2. Cont.
Reference Cell Source EV Isolation EV Characterization Key Findings
Pizzicannel-la et al., 2019
[56]
• hPDLSCs





• The CM from 15 × 103/cm2
hPDLSCs was centrifuged at
3000× g for 15 min; 2 mL of
ExoQuick TC was added to 10
mL of CM; incubated
overnight at 4 ◦C without
rotation, centrifuge at 1500× g
for 30 min, resuspend with 200
µL PBS





• hPDLSCs–EV: 100–710 nm; engineered PEI–EV:
1050–7700 nm by DLS.
• In vitro: increased expression of osteogenic
markers (RUNX2, COL1A1, BMP2/4, VEGFA
and VEGFR2) in hPDLSCs cultured in a collagen
membrane with EVs and PEI–EVs, as well as
increased protein levels of VEGF and VEGFR2.
• in vivo: EV and PEI–EV groups increased VEGF
and VEGFR2 protein expression at 6 weeks post
transplanting into a rat calvarial defect, as well as
enhanced vascular and bone formation. While
PEI–EV showed better bone and vascularization
than that of the EV group.
Wang et al., 2019 [57]
• Human PDL cells (hPDLCs)
were prepared from the PDL of
fully erupted lower third
molar teeth
• A mouse macrophage-like cell
line (J774.1)
• Human monocyte-like cell line
THP-1
• Exosome-depleted FBS was
prepared using the FBS
exosome depletion kit (Norgen,
Thorold, ON, Canada)
• The PureExo R exosome
isolation kit (101Bio, Mountain
View) was used for exosome
isolation.
• SN was centrifuged at 3000× g
for 15 min; 2 mL of SN mixed
with a solution of PureExo
isolation kit and incubated at
4 ◦C for 30 min, centrifuged at
5000× g for 3 min, air-dried,
re-suspension in 100 µL PBS;
centrifuge for 5 min at
5000× g;
• Processed on a PureExo
column, centrifuged at
1000× g for 5 min.
• TEM
• WB (CD9)
• ELISA using PS
CaptureTM exosome
ELISA kit for CD63
• D: 30 and 100 nm (average 50 nm).
• Cyclic stretch (CS) exposed PDL cells generated
30 times more exosomes compared to non-CS
treated normal PDL cells at 24 h
• CS hPDLC exosomes inhibited IL-1β production
in LPS/nigericin-stimulated J774.1 macrophages
and the nuclear translocation of NF-kB as well as
NF-kB p65 DNA-binding activity in
LPS-stimulated macrophages, suggesting that
exosomes suppress IL-1β production by
inhibiting the NF-kB signaling pathway.
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Table 2. Cont.
Reference Cell Source EV Isolation EV Characterization Key Findings
Kang et al., 2018 [58]
• hPDLSCs and THP-1 cells lines
• The passage not mentioned for
hPDLSCs
• hPDLSCs were treated with
1 µg/mL of LPS for 1 h and
CM was collected after 24 h of
incubation and filtered using a
0.22 µm filter.
• CM was centrifuged at 2000×
g for 10 min at 4 °C and
filtration through a 0.22 µm
filter; ultracentrifuged at
100,000× g for 60 min at 4 ◦C.
• NTA
• WB (CD81 and CD63)
• The median sEV particle sizes were 151.3 nm and
146.9 nm for the EVs from control hPDLSCs and
LPS-preconditioned hPDLSCs.
• sEV particle number was significantly decreased
in the sEV from LPS-preconditioned PDLSCs
compared to those from the control hPDLSCs.
• sEV from LPS-preconditioned hPDLSCs induced
M1 polarization in THP-1 cells, with increased
mRNA expression of IL-6 and TNF-α, and TNF-α
protein. The M1 polarization was abolished by
DNase I treatment of sEV.
Diomede et al., 2018 [59]
• hPDLSCs culturing on
collagen membranes
(Evolution-Evo).
• Donor: Five participants,
either patient for orthodontic
purposes or healthy volunteers.
Unclear age.
• Passage 2
• After 48 h of incubation, the
conditioned medium (CM; 10
mL) was collected from
hPDLSCs.
• CM was centrifuged at 3000×
g for 15 min; 2 mL ExoQuick
TC was added to 10 mL CM;
incubated overnight at 4 ◦C
without rotation, centrifuge at
1500× g for 30 min





• DLS analysis showed that hPDLSCs–EV had two
populations of vesicles, with an average diameter
of 90 ± 20 nm and 1200 ± 400 nm.
hPDLSCs–PEI–EV size: 250 ± 50 nm and 3600 ±
500 nm for two populations.
• Evo enriched with EV and PEI–EV showed high
biocompatibility and osteogenic properties both
in vitro and in vivo.
• PEI–EV promoted the expression of osteogenic
genes, such as TGFβ1, MMP8, TUFT1, TFIP11,
BMP2, and BMP4 after 6 weeks of in vitro
osteogenic differentiation in hPDLSCs.
• PEI–EV group led to an in vivo organized
extracellular matrix showing mineralization areas
and blood-vessel formation, with upregulated
BMP2/4 in collagen membrane enriched with
PEI–EV and hPDLSCs after 6 weeks in a rat
calvarial defect.
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Table 2. Cont.
Reference Cell Source EV Isolation EV Characterization Key Findings
Rajan et al., 2016 [60]
• hPDLSCs
• Donor: Five human
periodontal ligament biopsies




• CM was centrifuged at 3000×
g for 15 min; 2 mL ExoQuick
TC was added to 10 mL CM
recovered from hPDLSCs;
incubated overnight at 4 ◦C
without rotation, centrifuge at
1500× g for 30 min.





• EV size was not mentioned.
• After intravenous administration of
hPDLSCs–EV into EAE rats, pro-inflammatory
cytokines IL-17, IFN-γ, IL-1β, IL-6, and TNF-α
were reduced, while the anti-inflammatory
cytokine, IL-10, was upregulated. Meanwhile,
apoptosis-related STAT1, p53, Caspase 3, and Bax
expressions were attenuated.
• hPDLSCs–EV from MS patients and healthy
donors block experimental autoimmune
encephalomyelitis (EAE), a mouse model of MS,
by inducing anti-inflammatory and
immunosuppressive effects in the spinal cord and
spleen, and reverse disease progression by
restoring tissue integrity via remyelination in the
spinal cord.
Abbreviations: TGFβ, transforming growth factor β; MAPK, mitogen-activated protein kinase; mTOR, mechanistic target of rapamycin; FoxO, forkhead box protein O; VEGFA, vascular endothelial growth
factor A; Ras, Ras GTPase; LPS, lipopolysaccharide; MFG-E8, milk fat globule-EGF factor 8 protein; TLR4, Toll-like receptor 4; PKB/Akt, protein kinase B; GSK-3β, glycogen synthase kinase 3; ALP, alkaline
phosphatase; OPN, osteopontin; BSP, bone sialoprotein; CP23, cementum protein 23; BMP2, bone morphogenetic protein 2; RUNX2, runt-related transcription factor 2; COL1A1, alpha-1 type I collagen; VEGFR2,
vascular endothelial growth factor receptor 2; IL-1β, interleukin-1 beta; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α; MMP8, matrix metalloproteinase-8; TUFT1, Tuftelin 1; TFIP11, Tuftelin-interacting
protein 11; IL-17, interleukin-17; IFN-γ, interferon-γ; IL-10, interleukin-10; STAT1, signal transducer and activator of transcription 1; Bax, Bcl-2-associated X protein.
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Regarding the EV content, it seems that hPDLCs–EV contain miRNAs [52,53] and circu-
lar RNAs [51] that may alter the recipient cells functions. RNA sequencing of hPDLSCs–EV
(where EV size was unclear) revealed that hPDLSCs–EV contains 955 non-coding tran-
scripts, with five representative miRNAs, including MIR24-2, MIR142, MIR296, MIR335,
and MIR490 [53]. The hDPLSCs–EV–miR-17-5p can regulate the angiogenesis of human
umbilical vein endothelial cells (HUVECs) during inflammatory stimulation by TNF-α [52].
Furthermore, circular RNA and long non-coding RNAs (lncRNAs) were also found in the
sEV from hPDLSCs, after five and seven days of osteogenic differentiation, with 69–557
circRNAs and 2907–11,581 lncRNAs detected by RNA sequencing. Compared with the sEV
from hPDLSCs before osteoinduction, 3 sEV–circRNAs and 2 sEV–lncRNAs were upregu-
lated, while 39 sEV–circRNAs and 5 sEV–lncRNAs were downregulated after 5 and 7 days
of osteoinduction. RT-qPCR validation showed that three sEV–circRNAs (hsa_circ_0087960,
hsa_circ_0000437, and hsa_circ_0000448) were upregulated after osteogenic differentiation,
while one was downregulated (hsa_circ_0000448). However, three selected lncRNAs (small
nucleolar RNA host gene5—SNHG5, LOC100130992, and ATP6VB1-AS1) showed no differ-
ence between the groups [51].
There is increasing evidence demonstrating that hPDL(S)Cs–EV can modulate in vitro
angiogenesis (in HUVECs [52]), osteogenesis (in MG-63 OBs [54] and hPDLSCs [55,56,59]),
anti-inflammation (in LPS-treated hPDLSCs [55,60] and J774.1 macrophages [57]), and
immunoregulation (induced M1 polarization in THP-1 cells [58]) via modulating the
TGF-beta pathway, MAPK pathway, mTOR pathway and FoxO signaling pathways [51],
and PI3K/Akt signaling [55] and NF-kB signaling pathways [57]. The in vivo function of
hPDL(S)Cs–EV was explored, either in rat calvaria defect [56,59] or intravenous adminis-
tration in mouse multiple sclerosis disease [60] models. Pizzicannel-la et al. [56] created
a calvarial defect, with a diameter of 4 mm and a height of 0.25 mm in male Wistar rats
(300–350 g; n = 4 for each group). The hPDLSCs–EV and hPDLSCs–PEI–EV were loaded on
collagen membranes and transplanted into the rat calvaria defect for 6 weeks, leading to
enhanced bone and vascularization compared to the no-EV groups, with the PEI–EV group
inducing better osteogenesis and vascularization compared to the EV group. Diomede
et al. [59] revealed similar results, showing that hPDLSCs–PEI–EV leads to increased blood
vessel formation after 6 weeks of the transplantation of hPDLSCs–EV- and hPDLSCs–PEI–
EV-loaded collagen membranes into a rat calvarial defect. Rajan et al. [60] established a
mouse model of MS disease, and intravenous administration of hPDLSCs–EVs decreased
apoptosis and inflammation in the diseased mice.
In summary, the size of hPDL(S)Cs–EV ranges from 20 nm to 1600 nm when using
different EV isolation methods, with under-reporting of sufficient detail about the cell
source and cell culture conditions before CM collection. The hPDL(S)Cs–EV contains
miRNAs, circRNAs, and lncRNAs, and they modulate the angiogenesis, osteogenesis, and
inflammation of recipient cells, through TGF-β, MAPK, mTOR and FoxO pathways [51],
and PI3K/Akt [55] and NF-kB signaling pathway [57]. However, none of the three in vivo
studies [56,59,60] used either a periodontal defect or a periodontitis animal model.
5.2. Human Gingival Fibroblasts (hGFs)–sEV
Table 3 summarizes seven studies [61–67]) of EV from fibroblasts (hGFs [62,63] or
MSCs (hGMSCs [61,64–67]) from human gingiva tissues. There are two studies that inves-
tigated the in vivo role of hGMSCs–EV using animal models [66,67]. The cells from either
20-to-40-year-old donors [66] or unclear age human donors [62–65,67] were used at passage
2 [64], passage 4–6 [62], <6 passage [66], or unclear [63,65,67]. EV-depleted FBS [61,63,66],
FBS starvation [65], and unclear cell culture conditions [62,64,67] were applied in the
studies before CM collection for EV isolation. The size of hGFs/hGMSCs–EV varied
from different studies, as follows: <200 nm [61–63,66], 50–500 nm [65], unclear size [64],
and a combination of two populations (93 ± 24 nm and 1200 ± 400 nm) [67]. Engineered
hGMSCs–PEI–EV had the following two populations: 250± 50 nm and 3600 ± 500 nm [67].
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Table 3. The isolation, characterization, and function of EV from hGFs or hGSMCs.
Reference Cell Source EV Isolation EV Characterization Key Findings
Nakao et al., 2021
[61]
• Human gingival mesenchymal
stem cells (hGMSCs)
• Donor details are unclear
• Passage 4–6
• CM was collected after 48 h in
FBS-free media and centrifuged at
10,000× g for 30 min.
• hGMSCs exosomes were isolated
using MagCapture TM exosome
isolation kit PS (FUJIFILM Wako).
• TEM
• NTA
• WB (CD9, CD63 and
CD81)
• Mode of sEVs: 109 ± 3.1 nm and 104 ± 1.8 nm
for hGMSCs–sEVs and TNF-α pre-treated
hGMSCs-derived sEVs.
• In vitro: TNF-α stimulation increased the number
of hGMSCs–sEVs and exosomal CD73, as well as
induced anti-inflammatory M2 macrophage
polarization. The hGMSCs–sEVs–miR-1260b can
target Wnt5a-mediated RANKL expression.
• in vivo: in a ligature-induced mice periodontitis
model, a local injection of GMSC-derived
exosomes significantly reduced periodontal bone
resorption.
Yin et al., 2020 [62]
• hGFs
• Donor: Five normal gingival








• FACS (CD63 and
CD81)
• D: 50–200 nm
• IGF–GFs–Exo increased cell proliferation of
normal hGFs at 24 h and 48 h by MTS assay.
• The expression of Ki67, PCNA, Bcl-2, and Bax
were enhanced after 24 h treated with
IGF–GFs–Exo. After 48 h, the level of PCNA, Bcl-2
and Bax was significantly downregulated, while
the expression of Ki67 was not varied
significantly.
Zhuang et al., 2020
[63]
• hGFs
• Donor: Fresh human gingiva
from donors with wisdom
tooth extraction
• hBMSCs
• Donor: Fresh human bone
marrow from the iliac bone of
jaw cysts during the
reconstruction of bone defects
with hydroxyapatite powder
and bone marrow after surgery
curettage
• Exosome-depleted medium was
obtained after 25,000 r.p.m.
ultracentrifugation for 90 min. Then,
10 mL of CM was mixed with
ExoQuick exosome precipitation
solution and refrigerated overnight.
• CM was centrifuged at 1500 r.p.m.
for 30 min at 4 ◦C and then at 3000
r.p.m. for 5 min.
• TEM
• WB (CD63, CD81 and
tubulin)
• TEM of EV diameter: 50 to 200 nm.
• Irradiation-activated hGFs–exosome inhibited
osteogenic differentiation of hBMSCs for 7 days,
with reduced ALP, COL1 and RUNX2 gene
expression via an exosomal miR-23a/CXCL12
axis.
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Table 3. Cont.
Reference Cell Source EV Isolation EV Characterization Key Findings
Silvestro et al., 2020
[64]
• hGMSCs
• Donor: six healthy adult





• The conditioned medium (CM; 10
mL) after 48 h of incubation were
collected from hGMSCs at passage 2.
• The CM was centrifuged at 3000× g
for 15 min; 2 mL ExoQuick TC was
added to 10 mL of CM and
incubated overnight at 4 ◦C without
rotation; one centrifugation step was




• The size of EV was not mentioned.
• RNA sequencing analysis showed that 15,380
genes were identified in GMSCs–EVs. There were
1067, 886, 808, 768, 562, and 541 protein-coding
genes for hydrolase, enzyme modulators, the
transcription factor, transferase, the receptor and
the transporter, respectively. There were 1155
non-coding RNA genes for anti-sense RNAs,
lncRNAs and miRNAs (miR1302 family, miR451
family, miR24 family, miR219 family and miR194
family).
• hGMSCs–EV also contain mRNAs for proteins of
the interleukins, TGF-, BMPs, GDFs, Wnt, VEGF,
FGF, and neurotrophins are critical for basic or
neuronal, bone or vascular development.
Coccè et al., 2019 [65]
• Human MSCs were isolated
from gingival papilla (named
GinPaMSCs)
• Donor details are unclear
• GinPaMSCs cultured with FBS-free
media for 72 h cultures before EV
collection.
• CM was collected at 24 and 48 h of
incubation and centrifuged on a 100
kDa filter device at 5000× g for 15
min. The two fractions (i.e., EV: F >




• TEM of exosomes: 50 to 500 nm. DLS of EV:
200–300 nm. NTA detected the following 3
different EV populations: 135 nm, 200–300 nm,
and 435 nm.
• PTX was presented in PTX-treated
GinPaMSCs-secreted EVs.
• GinPaMSCs–EV/PTX have anti-cancer activity in
human pancreatic carcinoma and squamous
carcinoma cells.
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Reference Cell Source EV Isolation EV Characterization Key Findings
Mao et al., 2019 [66]
• hGMSCs: gingival tissues were
obtained from five healthy
human subjects aged from
20-to-40 years, who underwent
routine dental procedures
• A rat Schwann cell (SC) line
RT4-D6P2T
• hGMSCs: passage < 6
• SCs passage < 4
• hGMSCs cultured in media with 1%
exosome-depleted FBS (System
Biosciences, SBI) for 48 h to collect
CM.
• The CM was centrifuged at 1000× g
for 30 min; 20 mL of culture media
was filtered a Vivaspin 20
ultrafiltration device (100 kDa) and
centrifuged at 3000× g for 60 min to
get 1 mL of the concentrated
medium; mixed with 0.2 mL
ExoQuick-TC exosome precipitation
solution (5:1) and incubated
overnight at 4 ◦C; centrifuged at
1500× g for 30 min at 4 ◦C
• BCA assay
• NTA
• WB (CD 63 and CD9)
• GMSC-derived sEV had a mean size of 103.8 ±
2.1 nm by NTA.
• in vivo studies mimicking clinical nerve repair
showed that hGMSCs-derived sEV promoted
functional recovery, axonal repair and
regeneration of crush-injured mice sciatic nerves.
• in vitro: GMSC-derived EVs promoted
proliferation and migration of Schwann cells,
with upregulated c-JUN, Notch1, GFAP (glial
fibrillary acidic protein), and SRY
(sex-determining region Y)-box 2 (SOX2).
Diomede et al., 2018
[67]
• hGMSCs seeded on 3D poly
(lactide) (PLA) scaffolds
• Donor: gingival tissue biopsies
were obtained from healthy
adult volunteers with no
gingival inflammation
• After 48 h of incubation, EVs were
collected from hGMSCs at passage 2.
• centrifuged at 3000× g for 15 min; 2
mL ExoQuick TC was added to 10
mL CM and incubated overnight at
4 ◦C; 1500× g for 30 min to sediment
the EVs




• WB (CD9, CD63,
CD81, and TSG101)
• DLS of hGMSCs–EVs: 93 ± 24 nm and 1200 ±
400 nm; engineered hGMSCs–PEI–EV: 250 ± 50
nm and 3600 ± 500 nm.
• EV and PEI–EV increased calcium deposits after 6
weeks of osteogenic differentiation in hGMSCs,
with increased RUNX2 and BMP2/4 gene and
protein expression.
• RNA sequencing of the transcriptome of
hGMSCs, EV and PEI–EV revealed that 31 genes
were differentially expressed between groups.
GO analysis showed that these 31 genes involved
in “regulation of ossification” and “ossification”
were upregulated in the PEI–EV group compared
to hGMSCs group through the TGF-β signaling.
• in vivo results showed that PEI–EV with/without
hGMSCs in PLA scaffolds enhanced bone and
blood vessels formation in a rat cortical calvaria
defect by histology and microCT.
Abbreviation: MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; Ki-67, antigen KI-67/marker of proliferation Ki-67; PCNA, proliferating cell nuclear antigen;
CXCL12, C-X-C motif chemokine 12/ stromal cell-derived factor 1; FGF, fibroblast growth factor; GDNF, glial cell-derived neurotrophic factor; PTX, paclitaxel; c-JUN, jun proto-oncogene/AP-1 transcription
factor subunit; Notch1, Notch homolog 1(translocation-associated).
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RNA sequencing data from Silvestro et al. showed that hGMSCs–EV comprises
15,380 genes (for interleukins, TGF-β, BMPs, GDFs, Wnt, VEGF, FGF, and neurotrophins),
and 1155 non-coding RNA (lncRNAs and miRNAs—miR1302, miR451, miR24, miR219
and miR194) [64]. The miRNA microarray data from Nako et al. [61] showed that 655
universal differentially expressed miRNAs were found in Exo-TNF compared to Exo-Ctrl,
particularly miR-1260b (ranked in the top three of the most highly upregulated miRNAs, by
using TNF- α preconditioning). RNA sequencing from Diomede et al. [67] demonstrated
that 31 ossification genes were enhanced in hGMSCs–PEI–EV compared to hGMSCs-EV
through the TGF-β signaling pathway.
The in vitro functional assays showed that hGFs/hGMSCs–sEV facilitates cell prolifer-
ation (in hGFs [62] and Schwann cells line [66]), anti-osteoclastogenic [61] and osteogenic
differentiation (in hBMSCs [63] and hGMSCs [67]), as well as an anti-carcinogenesis effect
(in human pancreatic carcinoma and squamous carcinoma cells [65]). This may be mediated
by an miR-1260b/Wnt 5A/RANKL pathway [61], miR-23a/CXCL12 axis [63], interleukins,
TGF-β, BMPs, GDFs, Wnt, VEGF, FGF, and neurotrophins [64], and TGF-β signaling [67].
In their in vivo investigations, Nakao et al. [61] created a ligature-induced periodontitis
mice model, and locally injected hGMSCs–sEV or TNF-α-preconditioned GMSC-derived
exosomes (hGMSCs–sEV–TNF) into the palatal gingiva of the ligated second maxillary
molar. One week post-injection, both the interventions significantly reduced periodontal
bone loss compared to the PBS control group, while hGMSCs–sEV–TNF further reduced
the distance from the cementoenamel junction to the alveolar bone crest (CEJ–ABC) and
the number of tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts, indicat-
ing an anti-osteoclastic property for hGMSCs–sEV [61]. Moreover, Mao et al. [66] trans-
planted hGMSCs–sEV-loaded gelfoam sheets into the crush-injury sites of sciatic nerves
in C57BL/6J mice, and the EV group had comparable beneficial effects on the functional
recovery of the injured sciatic nerves of mice compared to the hGMSCs group. Further,
hGMSCs–sEV enhanced the expression of neuronal and Schwann cell markers (β-tubulin
III and S100 calcium-binding protein B—S100B) at one-month post-injury, compared with
hGMSCs controls, suggesting that hGMSCs–sEV can promote neuron regeneration in vivo.
Diomede et al. [67] loaded hGMSCs–EV or hGMSCs–PEI–EV into 3D-printed PLA scaffolds
with/without hGMSCs, and transplanted them into rat calvaria defects for 6 weeks. Both
the hGMSCs–EV and hGMSCs–PEI–EV groups enhanced bone and blood vessel formation,
yet hGMSCs–PEI–EV performed better than the EV group.
In summary, the EV diameter from hGFs/hGSMCs is different among studies, ranging
from 50 nm to 1600 nm. EV–mRNAs and EV–miRNAs [61,64,67] may contribute to their
in vitro and in vivo function in cell proliferation [62,66], and reduce bone resorption [61],
osteogenic differentiation [63,67] and nerve regeneration [66]. More in vivo studies are
required in order to explore the function of EV from gingival tissue-derived cells.
5.3. Human Dental Pulp Cells (hDPSCs)–sEV
Table 4 summarizes nine studies investigating EV from human primary DPSCs [68–76],
with three of these including in vivo models [69,72,76]. Cells were isolated from donors
who were 24–41 years old [69], 16–25 years old [70], 20 years old [71], 19–28 years old [73],
22–36 years old [75], or an unclear donor age [68,72,74,76]. The cells at passage 2 [71],
passage 3–6 [70], passage <4 [76], passage 3–7 [75], passage 3–5 [73], or unclear passage
number [68,69,72,74] were used in these studies. Prior to CM collection, the cells were
cultured in EV-depleted FBS [68,70–73] or FBS starvation [69,74–76]. The mode size of
hPDSCs–sEV was smaller than <200 nm in most studies [68–72,75], with one study report-
ing 50–400 nm [72], 80–400 nm [73], and 30–250 nm [74], and unclear EV size [76].
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Table 4. The isolation, characterization, and function of hDPSCs–EV.





• Human dental pulp
pluripotent-like stem cells
(hDPPSCs) from healthy





• The passage is not mentioned
• Exosome-depleted FBS was obtained after
ultracentrifugation at 100,000× g for 18 h at
4 ◦C.
• CM was filtered through 0.22 µm filter, mixed
with sucrose solution with 25% w/w in
deuterium oxide (D2O) and ultracentrifugation
at 100,000× g for 1.5 h at 4 ◦C and another
100,000× g for 1.5 h at 4 ◦C.
• NTA




• sEV from hDPPSCs spheroids culturing in KnockOut™
serum replacement (KO-medium) at both day 1–12 and
day 13–24 samples were detected similar particle sizes






• Donor: 5 healthy donors (male:
2; female: 3; age: 24~41 years)
and periodontitis teeth (n = 6),




named H-EV and P-EV.
• At 90% confluence, hDPSCs were washed three
times with PBS prior to culturing with
serum-free media for 48 h.
• CM was centrifuged at 300× g for 10 min;
2000× g for 10 min; centrifuged at 10,000× g for
30 min; ultracentrifuged at 100,000× g for 70








• Both H-EV and P-EV sizes ranged from 30 to 200 nm.
• hPDSCs–sEV from periodontitis patients promoted
endothelial cells proliferation and angiogenesis with
higher expression levels of VEGF and AngII
genes/proteins compared with hPDSCs–sEV from healthy
patients.
• in vivo: The vascularization of mouse skin defects and
wound healing were promoted by both H-EV and P-EV,
while the treatment with the latter brought a faster





• hDPSCs from healthy third
molars (n = 3, 16 to 25 years
old) were extracted
• Human bone marrow-derived
mesenchymal stem cells
(HBMMSCs). Passage 3–6
• Exosome-free medium (Invitrogen) was used
for hDPSCs culture for 48 h before CM
collection.
• CM centrifuged at 300× g for 10 min; 2000× g
for 30 min; total exosome isolation agent
(Invitrogen) was added; the mixture was
centrifuged at 10,000× g for 30 min
• TEM
• WB (CD9, and
Grp94)
• hDPSC–sEV ranged from 45 to 156 nm by TEM, with a
mean size of 90 nm.
• hDPSC–sEV encapsulated in fibrin gel promoted
hBMMSCs migration and proliferation.
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Table 4. Cont.





• Donor: one healthy patient
aged 20 years old, free of
periodontal or endodontic
problems.
• Exosomes secreted by hDPSCs during the
starvation of 48 h without FBS, marked as EX0.
Osteogenic-induced DPSC-derived exosomes
(OI-DPSC-Ex) after culturing with osteogenic
media with 15% exosome-free FBS. Exosomes
secreted by these osteogenic-induced DPSCs at
days 5 and 7 were extracted and marked as EX5
and EX7.
• CM was centrifugated at 3000× g for 20 min;
centrifuged at 16,500× g for 20 min; filtered
with a 0.2 micron filter to collect the filtrate;








• TEM and NTA detected that exosomes size range from 20
to 120 nm.
• The OI-DPSC-Ex induced the osteogenic differentiation of







• Donor: from exfoliated teeth of
healthy donors
• Passage not mentioned
• 80% confluent hDPSCs cultured with medium
supplemented with 10% exosome-free FBS
(centrifuged at 120,000× g for 18 h) for 3 days.
• CM was centrifuged at 300× g for 10 min;
centrifuged at 16, 500× g for 20 min;
ultracentrifuged at 120,000× g for 2.5 h at 4 ◦C











• NTA of EV: 50 to 400 nm, peaked at 155.4 nm.
• In an in vivo periodontitis mice model, DPSC-Exo/CS
promoted the regeneration of alveolar bone and
periodontal epithelium in the periodontitis mice model
after 10 days.
• DPSC-Exo/CS had anti-inflammatory effects and
facilitated the immune response by switching
macrophages from a pro-inflammatory phenotype to an
anti-inflammatory phenotype at both in vitro and in vivo






• Donor: healthy patients (aged
19–28 years old, n = 12)
impacted third molars
• LPS pretreated overnight in
hDPSCs. EV from LPS-treated
cells were named LPS-exo
• Passage 3–5
• hDPSCs at 70–80% confluence cultured for 48 h
in media exosome-depleted FBS (Systembio).
• CM was centrifuged at 500× g for 10 min at
4 ◦C, centrifuged at 2000× g for 10 min;
centrifuged at 10,000× g for 1 h at 4 ◦C and
filtrated through a 0.22 µm filter;
ultracentrifuged at 100,000× g for 2 h;
ultracentrifuged at 100,000× g at 4 ◦C for
70 min
• BCA assay





• EV: 80–400 nm, peaked at 116 nm.
• LPS-treated cells generated more exosomes particles.
• Both exo and LPS-exo facilitated the production of dentin
sialoprotein and mineralization of Schwann cells (SCs).
• LPS-exo had a higher promoted proliferation, migration
and odontoblast differentiation of Schwann cells (SCs)
compared to Exo only, with increased DSPP, DMP1, OCN,
and RUNX2 gene expression after 14 days.
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Table 4. Cont.




• hPDSCs were isolated from
healthy dental pulp tissues
and (n = 8) from the
caries-free teeth that need to be
extracted due to orthodontics
• hBMMSCs were isolated from
bone marrow aspirates of
healthy people (n = 8).
• At 80% confluence, the medium was replaced
with a serum-free medium for 48 h before CM
collection.
• The CM was centrifuged at 300× g for 10 min,
centrifuged at 16,500× g for 30 min at 4 ◦C;
passed through a 0.2 µm; ultracentrifuged at
4 ◦C at 100,000× g for 70 min; ultracentrifuged




• WB (CD9 and
CD63)
• NTA of EV: 30–250 nm, mean size of 135 nm.
• hDPSCs–EV suppressed the differentiation of CD4+ T cells
into T helper 17 cells (Th17), but stimulated the
polarization of CD4+ T cells into regulatory T cells (Treg).
• hDPSCs–EV and hBMMSCs–EV inhibited the secretions of
pro-inflammatory factors (IL-17 and TNF-α) and increased
anti-inflammatory factors (IL-10 and TGF-β) in CD4+ T
cells after 72 h of treatment.
• Both hDPSCs–EV and hBMMSCs–EV inhibited





• Donor: healthy pulp tissues
isolated from caries-free teeth
of patients (5 females, age
24–35 years; 5 males, age 22–36
years) undergoing extraction
of fully erupted third molars
• Passage 3–7
• Exosomes from hDPSCs in either growth
(UN-Exo) or odontogenic differentiation media
(OD-Exo) for 10 days
• Cells were washed in serum-free PBS and
cultured for 48 h in serum-free media.
• The Exo-spin (Cell Guidance) exosome isolation
reagent (no detailed description)
• WB (CD9 and
CD63)
• TEM
• UN-Exo and OD-Exo range from 30 to 150 nm in diameter
by TEM.
• OD-Exo promoted the odontogenic differentiation in
hDPSCs with increased RUNX2, DMP-1, DSP and ALP
gene expression.
• RNA sequencing analysis showed that 28 microRNAs
significantly changed in OD-Exo isolated under
odontogenic conditions, of which 7 miRNAs increased and
21 miRNAs decreased. The qRT-PCR analysis showed that
miR-5100 and miR-1260a levels in OD-Exo increased,
while miR-210-3p and miR-10b-5p decreased, which were
consistent with the miRNA sequencing. GO analysis
showed that the differentially expressed miRNAs are
associated with the TGFβ1 pathway.
• OD-exo activated the TGFβ1 pathway by upregulating
TGFβ1, TGFR1, p-Smad2/3, and Smad4 in DPSCs,
compared to the control group and UN-Exotreated group.
• Compared with UN-Exo, miR-27a-5p was expressed 11
times higher in OD-Exo.
• The luciferase reporter assay demonstrated that
miR-27a-5p can target the 3′-UTR of LTBP1 directly.
• This suggests that exosomal miRNAs promoted
odontogenic differentiation via the TGFβ1/smads
signaling pathway by downregulating LTBP1.
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Table 4. Cont.





• hDPSCs and primary hMSCs
are not clearly detailed.
• Both hDPSCs and hMSCs used
were passage <4
• Exosomes were isolated from hDPSCs in either
growth (DPSC-Exo) or odontogenic
differentiation media (DPSC-OD-Exo) for
4 weeks. Cells were washed in serum-free
media and cultured for 24 h in serum-free
media before CM collection.
• ExoQuick-TC exosome isolation reagent
(non-detailed description)
• WB (CD63 and CD9)
• TEM
• Size of EV was not demonstrated.
• The endocytosis of exosomes was
dose-dependent and manner-saturable for both
hMSCs and hDPSCs in vitro, which initiated the
MAPK pathway through the caveolar endocytic
mechanism.
• hDPSCs–EV can bind to fibronectin and type I
collagen via an exosomal integrin-mediated
process.
• DPSC-Exo and DPSC-OD-Exo induce increased
expression of odontogenic marker genes in
DPSCs in 3D culture within type I collagen
hydrogels.
• DPSCs-Exo and DPSC-OD-Exo in a collagen
membrane on a filled root canal spaces of human
tooth root slices were implanted subcutaneously
in athymic nude mice for 2 weeks. DPSC-Exo and
DPSC-OD-Exo triggered increased expression of
odontogenic differentiation marker proteins
DMP1 and DPP, and only the DPSC-OD-Exo
group improved active blood vessels formation
and endothelial cell marker von Willebrand factor
(vWF).
• DPSC-Exo and DPSC-OD-Exo in hMSCs after 48
h of in vitro treatment increased in the expression
levels of several growth factors and ECM proteins
along with the transcription factor Runx2.
Abbreviations: circPAR1, circular Prader–Willi/Angelman region-1; DMP-1, dentin matrix acidic phosphoprotein 1; DSPP, dentin phosphophoryn; TGFR1, transforming growth factor beta receptor I; p-Smad2/3,
mothers against decapentaplegic homolog 2/3 or SMAD family member 2/3; Smad4, SMAD family member 4/mothers against decapentaplegic homolog 4; UTR, untranslated region; LTBP1, latent TGF-beta
binding protein.
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The hPDSCs–EV modulates angiogenesis in endothelial cells [69], migration/proliferation
(in hBMMSCs [70], Schwann cells (SCs) [73], and CD4+ T cells [74]), osteogenic differ-
entiation in hDPSCs [71], anti-inflammation (in DPSCs [72] and CD4+ T cells [74]), and
odontogenic differentiation of Schwann cells (SCs) [73], hDPSCs [75,76], and hMSCs [76].
This may be regulated through hDPSCs–sEV–circPAR1 binding with hsa-miR-31 [71],
hDPSCs–sEV–miR-1246 [72] and hDPSCs–sEV–miR-27a-5p [75]. RNA sequencing data
from Hu et al. [75] demonstrated that 7 increased sEV–miRNAs and 21 decreased sEV–
miRNAs were found in odontogenic differentiated hDPSCs–sEV, and these miRNAs are
associated with the TGFβ1/smads signaling pathway. The authors concluded that sEV–
miR-27a-5p can modulate odontogenic differentiation via the TGFβ1/smads signaling
pathway, by downregulating latent-transforming growth factor beta-binding protein 1
(LTBP1).
With respect to in vivo studies, Zhou et al. [69] created a full-thickness excisional skin
wound-healing model in male C57BL/6 mice (8 weeks old), and then subcutaneously
injected hDPSCs–sEV (200 µg in 100 µL) from healthy or periodontitis patients derived
hDPSCs–sEV (200 µg in 100 µL PBS) for 4, 9, and 14 days. Both the sEV groups promoted
the wound healing process and vascularization compared to the PBS control group, while
hDPSCs–sEV from the periodontitis patients increased the wound closure rate and the
number of newly formed microvessels, with more CD31- and VEGF-positive cells com-
pared to the sEV from a healthy patient. Shen et al. [72] established a ligation-induced
periodontitis model in 6–8-week-old male C57BL/6J mice, and a chitosan hydrogel (CS)
loaded with 50 µg of hDPSCs–sEV (hPSDCs–sEV–CS group) was locally injected after liga-
ture removal, with a local injection of PBS or hPSDCs–sEV used as the controls. The results
showed that the hDPSCs–sEV–CS group led to increased bone formation, a thick layer of
epithelial layers, less inflammatory cells, and a lower amount of TRAP-positive osteoclasts,
at 10 days post-treatment. Furthermore, hPSDCs–sEV–CS treatment significantly reduced
pro-inflammatory cytokines (IL-23, IL-1α, TNF-α, IL-12, IL-1β, IL-27, and IL-17), and
NF-κB p65 and p38 MAPK signaling, in periodontal tissues compared with other groups.
RNA sequencing analysis of the periodontium showed that 7351 differentially expressed
genes (DEGs) were found between the hDPSCs–sEV–CS and CS groups. GO term enrich-
ment analysis of the top 200 DEGs demonstrated that they are associated with chemotaxis
pathways and the immune response, which were downregulated in the hDPSCs–sEV–
CS group. Most importantly, hDPSCs–sEV–CS induced macrophages converting from a
proinflammatory phenotype to an anti-inflammatory phenotype in the periodontium of
periodontitis mice, with more CD206+ anti-inflammatory macrophages and significantly
decreased CD86+ in pro-inflammatory macrophages [72]. This indicates that hDPSCs–
sEV can promote bone formation, epithelium re-growth, and reduce inflammation in a
periodontitis mice model. Furthermore, Huang et al. [76] loaded hDPSCs–EV into clinical-
grade type I collagen membranes, and then placed them on a human tooth root slice (3–4
mm in thickness), before subcutaneously transplanting into athymic nude mice for 2 weeks.
They resulted in enhanced dental-pulp-like tissues, with increased odontogenic proteins
(dentin matrix acidic phosphoprotein 1—DMP1, and dentin phosphophoryn—DSPP) and
endothelial cell marker protein (von Willebrand factor—vWF).
To summarize, hDPSCs–EV, ranging from 30 nm to 400 nm among nine studies,
and containing circRNA [71], miRNAs [72,75], and mRNAs [72], may modulate an-
giogenesis [69], migration/proliferation [70,73,74], osteogenic differentiation [71], anti-
inflammation [72,74] and odontogenic differentiation [73,75,76] in recipient cells. Among
the three in vivo studies, the skin wound-healing model [69], periodontitis disease model [72],
and subcutaneous transplantation [76] were employed, and the results showed that
hPDSCs–EV can promote angiogenesis, osteogenesis, dentin-pulp regeneration, and reduce
inflammation and osteoclastic activity. Further in vivo studies are required to validate the
function of hDPSCs–EV.
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5.4. SHED/SCAP/DFCs–sEVs
Table 5 summarizes seven investigations (five in vivo studies) examining sEVs from
dental cells, including SCAP [77,78], SHED [79–82], and DFCs [83]. Cells were isolated
from 5–8-year-old donors [81], 12–15 years old [77,78], 13–19 years old [83], or unknown
age [79,80,82], at passage 3–4 [79], 4–7 [80], 4 [81], 3–6 [82], 5 [83], or unknown [77,78].
EV-depleted FBS [77,79,81,82] and FBS-starvation [78,80,83] were applied for CM collection.
The size of SHED/SCAP/DFCs–sEVs was smaller than 200 nm in all the studies;
these sEVs promote angiogenesis in HUVECs [77,82], anti-inflammation in mBMSCs [80]
and chondrocytes [81], osteogenesis in PDLCs [79], mBMSCs [80] and rBMSCs [82], and
dentinogenesis in BMMSCs [78,83] in vitro, by the Cdc42 pathway [77], Wnt/β-catenin
and BMP/Smad signaling pathways [79], miR-100–5p/mTOR pathway [81], and AMPK
pathway [82].
The function of SCAP–sEVs was investigated in vivo on gingival soft tissue [77] and
dentin-pulp regeneration [78]. Liu et al. [77] created full-thickness circular gingival wounds
in C57BL/6J mice, using a biopsy punch (soft tissue defects with a diameter of 2.0 mm).
Following this, 40 µg of SCAP–sEVs, SCAP–siCdc42–sEVs, or PBS, was injected submucos-
ally into the palates of the wounds sites. Seven days post-injection, SCAP–sEVs promoted
palatal gingival tissue regeneration by enhancing vascularization in the early phase [77].
Zhuang et al. [78] loaded 50 µg/mL SCAP–sEVs and 4 × 105 BMMSCs with gelatin sponge
onto a dentin slice, before subcutaneously transplanting them into immunodeficient mice.
Significant dentin-pulp regeneration was observed 12 weeks post-transplantation in the
SCAP–sEVs group compared to the PBS control group.
The action of SHED–sEVs on periodontitis disease and periodontal defect in vivo has
been investigated in a mouse [80] and rat model [82], respectively. Wei et al. [80] locally
injected 20 µg of SHED–sEVs into buccal and lingual sides of the first molar once per week,
over 2 weeks, in ligature-induced periodontitis mice. After 2 weeks, SHED–sEVs reduced
bone loss, with a decreased CEJ–ABC distance compared to the controls. Moreover, Wu
et al. [82] generated a periodontal defect (4 × 2 × 1.5 mm3) in their rat model, at the buccal
alveolar bone of the first-to-third mandibular molars. SHED–sEVs were loaded into a
β-TCP scaffold before placing them into the periodontal defect for four weeks, resulting
in enhanced neovascularization and new bone formation compared to the β-TCP/PBS
scaffold.
In their study, Shi et al. [83] injected gelatin hydrogels (100 µL), loaded with LPS–
DFCs–sEVs (sEVs derived from LPS-treated DFCs) or DFCs–sEVs, into the periodontal
pocket of the right maxillary second molar in a ligature-induced periodontitis rat model.
The intervention was once a week for up to 8 weeks, and resulted in significantly reduced
alveolar bone loss and TRAP-positive osteoclasts, as well as enhanced well-oriented PDL
fibers in the LPS–DFCs–sEVs group.
In summary, SHED/SCAP/DFCs–sEVs are smaller than 200 nm, and those containing
miR-100–5p [81] may modulate angiogenesis [77,82], inflammation [80,81], osteogene-
sis [79,80,82], and dentinogenesis [78,83] in vitro. More importantly, five in vivo studies
showed that SHED/SCAP/DFCs–sEVs can promote angiogenesis [77,82], dentin-pulp
complex [78], alveolar bone [82], and well-organized PDL fiber formation [82]. It is noted
that two studies utilized a ligature-induced periodontitis disease model [80,83] and one
study used a periodontal defect model [82]. More studies are needed to further validate
the in vivo functional role of SHED/SCAP/DFCs–sEVs.
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Table 5. The isolation, characterization, and function of sEVs from SHED, SCAP and DFCs.





• Stem cells from apical papilla (SCAP)
• Donor: healthy third molars with
immature roots from healthy donors
aged 12 to 15 years
• Passage number is unclear
• SCAP cells were cultured in exosome-free
medium for 48 h and CM was centrifuged at
4 ◦C in an ultracentrifuge at the following three
different speeds: 3000× g for 20 min, 20,000× g







• sEVs mode: 120.1 nm; mean: 139.2 ± 62.5 nm
• in vivo: SCAP–sEVs promoted vascularization to
accelerate tissue regeneration of the palatal
gingiva via Cdc42-mediated vascularization in a
mouse gingival wound healing model.
• in vitro: SCAP–sEVs enhanced the cell migration







• Donor: Human impacted third molar
with immature roots were collected
from healthy patient (12–15 years old)
• Passage number is unclear
• SCAP cells at 60–80% confluence were cultured
with serum-free media for 48 h before CM
collection.
• The CM was centrifuged sequentially at 4 ◦C:
3000× g for 20 min, 20,000× g for 30 min, and





• WB (CD9, and
Alix)
• sEVs peaked at 120.6 nm.
• SCAP-Exo promoted mouse BMMSC-based
dentine-pulp complex regeneration in vivo and





• Stem cells from human-exfoliated
deciduous teeth (SHED)
• hPDLCs
• Donor: age is unclear; pulp tissue from
non-carious primary teeth extracted
from children for orthodontic reasons
• Passage: 3–4
• SHED and hPDLCs cells were cultured in 15%
and 10% exosome-free media, respectively.
• The CM was centrifuged at 300× g for 10 min,
2000× g for 10 min, and 20,000× g for 30 min








• DLS revealed that the SHED–sEVs diameter
ranges from 40 to 140 nm.
• SHED–sEVs promote in vitro osteogenic
differentiation in PDLCs via Wnt/β-catenin and
BMP/Smad signaling pathways.
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• SHED were purchased
• Mouse bone marrow stromal cells
(mBMSCs) were isolated from femur
and tibia bone marrow of CD-1 mice
(9–10 months old).
• Passage: 4–7 for SHED–sEVs
• At 70% confluence, SHED cells were cultured in
serum-free media for 24 h.
• The CM was collected and centrifuged at 300×
g for 10 min, 2000× g for 10 min, 10,000× g for
60 min before a 0.22 µm filter. 100,000× g for





• in vivo: local injection of SHED–sEVs rescued
ligature-induced periodontitis bone loss in mice.
• in vitro: SHED–sEVs promoted cell proliferation,
osteogenesis and reduced adipogenesis and





• SHED was purchased from a cell bank
and cells were from nine normal human
deciduous incisors collected from 5- to
8-year-old individuals.
• Chondrocytes were isolated from
cartilage tissues of five patients with
condylar fracture
• Passage 4 for both SHED and
chondrocytes
• SHED cells were confluent before culturing in
exosome-free media for 48 h.
• CM was collected and centrifuged at 4 ◦C: 300×
g for 10 min, 2000× g for 10 min, 20,000× g for







• The sizes of SHED–sEVs range from 30 to 100 nm.
• SHED–sEVs inhibited pro-inflammatory
cytokines expression in chondrocytes in vitro via
an exosomal miR-100-5p and mammalian target





• SHED and HUVECs cells: commercial
cells
• rBMSCs: femoral bones of SD rats
• Passage: 3–6 (SHED)
• Exosome-depleted FBS was obtained after
ultracentrifuging at 100,000× g for 12 h.
• CM collection was not clear.
• The CM was centrifuged at 300× g for 10 min,
and 2000× g for 15 min, 10,000× g for 30 min
and concentrated using ultrafiltration, followed








• D: 50 to 200 nm, with two peaks, at 101 and
144 nm.
• in vitro: SHED—sEVs promoted proliferation,
migration and angiogenesis in HUVECs and
osteogenic differentiation in rBMSCs via
adenosine monophosphate-activated protein
kinase (AMPK) pathway.
• in vivo: SHED–sEVs promoted
neovascularization and new bone formation in a
periodontal bone defect rat model.
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Table 5. Cont.




• Dental follicle cells (DFCs)
• Donor: dental follicle tissue obtained
from the immature third molars was
selected in young patients (age
13−19 years).
• hPDLCs from chronic periodontitis (age
40−55 years).
• Passage: 5 (for DFCs)
• At 80% confluence, DFCs were treated
with/without LPS for 24 h prior to culturing in
serum-free media for 48 h.
• The CM was centrifuged at 2000× g for 30 min
and filtered by a 0.22 µm filter. Then the
supernatant was ultrafiltered using 100 KD
ultrafiltration at 5000× g or 30 min. Then total
exosome isolation reagent was added to the
concentrated solution and put into a 4 ◦C
refrigerator overnight and centrifuged at






• The diameter of DFCs–sEVs was peaked at
120nm.
• LPS precondition increased the secretion of sEV
from DFCs.
• in vitro: LPS–DFCs–sEVs promoted proliferation,
migration and osteogenic differentiation in
periodontitis derived hPDLCS.
• in vivo: LPS–DFCs–sEVs enhanced orientated
periodontal ligament formation, periodontal bone
formation, as well as reduced TRAP-positive
osteoclasts cells and RANKL/OPG expression.
Abbreviations: Cdc42, cell division control protein 42 homolog; RANKL/OPG, receptor activator of nuclear factor kappa-B ligand/osteoprotegerin.
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6. Summary and Discussion
Periodontal cells (PDLCs/SCAP and GFs/GMSCs) and dental pulp (DPSCs/SHED)-
derived EVs can play an important role in augmenting the function of recipient cells,
such as proliferation and osteo/odontogenic differentiation, as well as anti-inflammation
and anti-cancer properties [51–83]. In particular, one study of GMSCs–sEVs [61] and
DPSCs–sEVs [72], two studies of SHED–sEVs [80,82], and one study of DFCs–sEVs [83]
can promote alveolar bone, vasculature and well-organized PDL fibers regeneration, and
reduced inflammation in a periodontitis animal model or a periodontal defect model. As
such, these EVs may serve as potential ‘cell-free’ therapeutics to facilitate periodontal
regeneration; however, more in vivo studies are required to confirm this concept.
As stated in the latest MISEV 2018 guidelines [6], it is critical to clearly describe the
primary cell source (i.e., donor age, health status, gender), primary cell passage number, cell
culture conditions (using either EV-depleted FBS or FBS starvation before CM collection),
and detailed EV isolation and characterization protocols. Among 33 studies in our review,
only two studies used human or mouse cell lines [54,57], and 31 studies isolated EV from
primary cells, with only 12 out of 31 studies stating a clear age range for the human or
mouse donors [51,55,66,69–71,73,75,77,78,81,83], and 13 out of 31 studies were unclear
about cell passage numbers [55,57,58,60,63,65,67–69,72,74,77,78]. Since FBS is largely EV
contaminated, EV-depleted FBS or FBS starvation should be used for cell culture before
CM collection. EV-depleted FBS was used in 12 studies [61,63,66,68,70–73,77,79,81,82],
FBS starvation in 8 studies [65,69,74–76,78,80,83], and unclear cell culture conditions in 11
studies. Although all the studies used the two most common sEV (or exosome) isolation
methods (precipitation and ultracentrifugation), the EV size in these studies (excluding
studies with no EV characterization) is not consistent, with 22 studies generating <200 nm
sEVs [51,54,55,57,58,61–63,66,68–72,75,77–83]. This may be attributed to the different CM
collection, EV isolation and characterization methods among the studies. Thus, appropriate
methods should be chosen to prepare CM, and isolate and characterize cell-derived EV
according to the MISEV guidelines. Our review has defined <200nm EV as sEV (small EV)
and unclear size or >200 nm as simply EV.
Among 33 studies, 12 studies performed in vivo research to investigate the EV function
of hPDLCs–sEV [56,59,60], hGMSCs–EV [66,67], hDPSCs–EV [69,72,76], SCAP–sEVs [77,78],
SHED–sEVs [80,82] and DFCs–sEVs [83]. Furthermore, three studies engineered the EV
using polyethyleneimine (PEI), yielding PEI–EV [56,59,67], and all three studies reported
that the PEI–EV group enhanced in vivo osteo/odontogenic and angiogenic properties
compared to the EV group. Animal studies employed either defect or disease models, such
as calvaria defects [56,59,67], nerve injury model [66,67], skin wound-healing model [69],
subcutaneous transplantation [76], and multiple sclerosis [60], ligation-induced periodonti-
tis [69,72,80,83] and a periodontal defect [82].
EVs were administrated either by loading into biomaterials, such as collagen mem-
brane [56,59,76], gelfoam sheets [66], gelatin sponge [78] and 3D-printed PLA scaffold [67],
or via intravenous administration [60], subcutaneous injection [69], local injection [61,72,80,83],
or submucosal injection [77]. More pre-clinical models (i.e., periodontal defects or peri-
odontitis disease models) and EV delivery systems need to be investigated to explore
the potential of periodontal cell-derived EV in the regeneration of anatomically complex
tissues, such as the periodontium.
All of the above factors are critical for a successful therapeutic outcome; thus, it is
of great importance to follow the relevant guidelines and consider the above-discussed
variables with more comparisons between different parameters.
7. Conclusions and Future Perspectives
This review demonstrates that sEV can be isolated from periodontal and pulp cells,
with 11 studies investigated the EV cargos, including sEV–miRNA [52,53,61,63,64,72,75,81],
EV–circRNA [51,71], EV–lncRNA [51] and EV–mRNA [67,72]. We summarize the com-
mon EV–miRNA and EV–circRNA within periodontal (or dental pulp) cells (Figure 4a,b).
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From the included studies, except for one common EV–miRNA (miR-1260b) between
DPSCs/SHED and GFs/GMSCs, there appears to be no common EV–miRNA detected
between these cell types (shown in Venn diagram, Figure 4a). We also listed reported EV–
miRNAs and EV–circRNAs from PDL(S)Cs–EV and hDPSCs—EV (Figure 4b). However,
this needs further confirmation with more studies. Furthermore, 38 EV–miRNAs, 69–557
EV–circRNAs, 254–15,380 EV–mRNAs and 2907–11,581 EV–lncRNAs were reported for
EV from periodontal (dental pulp) cells by RNA sequencing analysis. We have outlined
that these EVs possess anti-inflammation, osteo/odontogenesis, anti-osteoclastogenesis,
angiogenesis and immunomodulatory functions in vitro and in vivo. Thus, we propose
that periodontal cell-derived EVs can modulate the cell function via EV cargos (Figure 4c).
However, more studies for periodontal cell-derived EVs are required to further confirm
this concept.
Given that cell source, CM collection, and EV isolation and characterization are critical
in obtaining pure EV populations, future studies should take these factors into account
and follow the latest MISEV guidelines. Researchers should consider adding EV purity
(EV particles per µg protein), DNase/RNase/proteinase treatment and EV engineering
before in vivo therapeutic research. Although current research has not yet standardized
these factors, data from all 33 studies in this review suggest that periodontal (dental pulp)
cell-derived EVs can function as potential therapeutics to promote periodontal regeneration
and impart anti-inflammatory properties. However, investigating the effect of periodontal
cell-derived EV on in vivo periodontal regeneration models is required to understand their
potential therapeutic role in periodontal regeneration.
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